Tags

Type your tag names separated by a space and hit enter

Spotlight on topical pimecrolimus in pediatric atopic dermatitis.
Am J Clin Dermatol 2010; 11(4):295-8AJ

Abstract

Topical pimecrolimus 1% cream (Elidel) [hereafter referred to as topical pimecrolimus] is a nonsteroidal alternative in the treatment of pediatric atopic dermatitis. In vehicle-controlled, short-term, continuous-use trials in pediatric patients with mild to moderate atopic dermatitis, topical pimecrolimus was effective in treating disease symptoms. Topical pimecrolimus was effective in preventing disease flares and reducing the need for topical corticosteroids in longer term, intermittent-use trials. In addition, topical pimecrolimus was associated with improvements in the health-related quality of life of pediatric patients with atopic dermatitis and their parents. In vehicle-controlled trials, topical pimecrolimus was generally as well tolerated as vehicle. Topical pimecrolimus showed similar efficacy to topical tacrolimus 0.03% ointment in a short-term, continuous-use trial and the two agents had a generally similar tolerability profile. Although comparative data between topical pimecrolimus and topical corticosteroids are lacking in pediatric patients, and the long-term tolerability (beyond 1-2 years) of topical pimecrolimus is yet to be established, topical pimecrolimus is a useful agent in the management of pediatric patients with mild to moderate atopic dermatitis who do not achieve satisfactory treatment with other topical pharmacologic treatments, including topical corticosteroids.

Authors+Show Affiliations

Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nzNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20509720

Citation

Yang, Lily P H., and Monique P. Curran. "Spotlight On Topical Pimecrolimus in Pediatric Atopic Dermatitis." American Journal of Clinical Dermatology, vol. 11, no. 4, 2010, pp. 295-8.
Yang LP, Curran MP. Spotlight on topical pimecrolimus in pediatric atopic dermatitis. Am J Clin Dermatol. 2010;11(4):295-8.
Yang, L. P., & Curran, M. P. (2010). Spotlight on topical pimecrolimus in pediatric atopic dermatitis. American Journal of Clinical Dermatology, 11(4), pp. 295-8. doi:10.2165/11204640-000000000-00000.
Yang LP, Curran MP. Spotlight On Topical Pimecrolimus in Pediatric Atopic Dermatitis. Am J Clin Dermatol. 2010;11(4):295-8. PubMed PMID: 20509720.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Spotlight on topical pimecrolimus in pediatric atopic dermatitis. AU - Yang,Lily P H, AU - Curran,Monique P, PY - 2010/6/1/entrez PY - 2010/6/1/pubmed PY - 2010/8/27/medline SP - 295 EP - 8 JF - American journal of clinical dermatology JO - Am J Clin Dermatol VL - 11 IS - 4 N2 - Topical pimecrolimus 1% cream (Elidel) [hereafter referred to as topical pimecrolimus] is a nonsteroidal alternative in the treatment of pediatric atopic dermatitis. In vehicle-controlled, short-term, continuous-use trials in pediatric patients with mild to moderate atopic dermatitis, topical pimecrolimus was effective in treating disease symptoms. Topical pimecrolimus was effective in preventing disease flares and reducing the need for topical corticosteroids in longer term, intermittent-use trials. In addition, topical pimecrolimus was associated with improvements in the health-related quality of life of pediatric patients with atopic dermatitis and their parents. In vehicle-controlled trials, topical pimecrolimus was generally as well tolerated as vehicle. Topical pimecrolimus showed similar efficacy to topical tacrolimus 0.03% ointment in a short-term, continuous-use trial and the two agents had a generally similar tolerability profile. Although comparative data between topical pimecrolimus and topical corticosteroids are lacking in pediatric patients, and the long-term tolerability (beyond 1-2 years) of topical pimecrolimus is yet to be established, topical pimecrolimus is a useful agent in the management of pediatric patients with mild to moderate atopic dermatitis who do not achieve satisfactory treatment with other topical pharmacologic treatments, including topical corticosteroids. SN - 1175-0561 UR - https://www.unboundmedicine.com/medline/citation/20509720/Spotlight_on_topical_pimecrolimus_in_pediatric_atopic_dermatitis_ L2 - https://dx.doi.org/10.2165/11204640-000000000-00000 DB - PRIME DP - Unbound Medicine ER -